Xingsheng Hu,Lin Wang,Lin Lin,Yuankai Shi. Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers. Oncol Transl Med, 2014, 13: 185-188. |
Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers |
|
View Full Text View/Add Comment Download reader |
KeyWord: |
Author Name | Affiliation | Xingsheng Hu | Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10021, China | Lin Wang | Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10022, China | Lin Lin | Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10023, China | Yuankai Shi | Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10024, China |
|
Hits: 7400 |
Download times: 8195 |
Abstract: |
Histone deacetylase (HDAC) inhibitors, which represent a structurally diverse group of molecules, have emerged as a novel therapeutic class of molecules with significant anticancer potential. Vorinostat and romidepsin, known as the first generation of HDAC inhibitors, were approved in the United States for the treatment of T-cell lymphomas. Preliminary activity of HDAC inhibitors has also been observed in non-small cell lung cancer (NSCLC) in combination with the existing treatment regimens, of which is the focus of the current review. |
Close |
|
|
|